Every meaningful development in the 2026 peptide regulatory story, FDA actions, enforcement, and industry shifts, explained in plain language, with what each means for legitimate access.
The committee considers whether to recommend a group of peptides for the 503A bulk-substances list licensed pharmacies may compound. The outcome is advisory, any change still requires formal rulemaking afterward.
One email when the advisory committee decides, plus plain-language updates as the story develops.